| Literature DB >> 34959872 |
Frédéric N Daussin1, François Péronnet2, Antoine Charton3,4, Evelyne Lonsdorfer4,5, Stéphane Doutreleau6, Bernard Geny4,5, Ruddy Richard7.
Abstract
Several brands of water enriched with O2 (O2-waters) are commercially available and are advertised as wellness and fitness waters with claims of physiological and psychological benefits, including improvement in exercise performance. However, these claims are based, at best, on anecdotal evidence or on a limited number of unreliable studies. The purpose of this double-blind randomized study was to compare the effect of two O2-waters (~110 mg O2·L-1) and a placebo (10 mg O2·L-1, i.e., close to the value at sea level, 9-12 mg O2·L-1) on the cardiopulmonary responses and on performance during high-intensity exercise. One of the two O2-waters and the placebo were prepared by injection of O2. The other O2-water was enriched by an electrolytic process. Twenty male subjects were randomly allocated to drink one of the three waters in a crossover study (2 L·day-1 × 2 days and 15 mL·kg-1 90 min before exercise). During each exercise trial, the subjects exercised at 95.9 ± 4.7% of maximal workload to volitional fatigue. Exercise time to exhaustion and the cardiopulmonary responses, arterial lactate concentration and pH were measured. Oxidative damage to proteins, lipids and DNA in blood was assessed at rest before exercise. Time to exhaustion (one-way ANOVA) and the responses to exercise (two-way ANOVA [Time; Waters] with repeated measurements) were not significantly different among the three waters. There was only a trend (p = 0.060) for a reduction in the time constant of the rapid component of VO2 kinetics with the water enriched in O2 by electrolysis. No difference in oxidative damage in blood was observed between the three waters. These results suggest that O2-water does not speed up cardiopulmonary response to exercise, does not increase performance and does not trigger oxidative stress measured at rest.Entities:
Keywords: VO2 kinetics; endurance exercise; performance; reactive oxygen species
Mesh:
Substances:
Year: 2021 PMID: 34959872 PMCID: PMC8704091 DOI: 10.3390/nu13124320
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Studies of the effects of O2-water ingestion on performance and on the response to exercise.
| Reference | Water Ingested | Reported (1) | Computed (2) | Observations |
|---|---|---|---|---|
| Askew et al. | Stabilized O2 in water | 30,000 ppm | ~53,700 mg·L−1 | No significant difference between the O2-water and the placebo in |
| Duncan | Oxygen-enhanced water | Not reported | ? | 5 km run (min:s) |
| Fleming et al. | Activate Stabilized Water (ASO): | 35 g in 62 g | 565 mg·L−1 | 5-km run: Lactate clearance (t1/2 in seconds) |
| Fuller 2010 [ | Activate Stabilized Water (ASO): | 5 mg·L−1 | 5 mg·L−1 | Trend for a longer time to exhaustion during a graded test to VO2max with the O2-water than the placebo (451 vs. 429 s) |
| Hampson et al. 2003 [ | Oxygenated water | 1,184 mmHg (3) | 88 mg·L−1 (3) | No significant difference between the O2-water and the placebo in |
| Jenkins et al. | Oxygenized water | Not reported | ? | Higher hemoglobin saturation in arterial blood at the end of exercise at 100%VO2max with the O2-water than the placebo (94 vs. 87%) |
| Leibetseder et al. 2006 [ | Oxygenated water | 160 mg·L−1 | 160 mg·L−1 | Higher VE/VO2 at submaximal workload and higher lactate |
| McNaughton et al. 2007 [ | Superoxygenated water | 150,000 ppm (4) | 266,000 mg·L−1 | No significant difference for a 45-min exercise at 70%VO2max followed by a 15-min time trial to exhaustion between the O2-water and the placebo |
| Mielke et al. | Oxygenated water | 13.1 mg·L−1 | 13.1 mg·L−1 | No significant difference in response to a graded exercise to VO2max or in exercise time to exhaustion at 90%VO2max between the O2-water and the placebo |
| Willmert et al. 2002 [ | Super oxygenated water | 13.5 mL·L−1 | 19.3 mg·L−1 | No significant difference between the O2-water and the placebo in |
| Wing-Gaïa et al. 2005 [ | Purified oxygen water | Not reported | ? | No significant difference in performance or in response to a time trial at 57–59%VO2max in hypoxic condition (~76 min) between the O2-water and the placebo |
| Zhang et al. | Hyperoxia solution | 170 mL·0.5 L−1 | 481 mg·L−1 | Lower plasma lactate concentration in response to a 5 km run at altitude (2000 and 4000 m) with the O2-water than |
(1) Values reported by the authors. (2) Values computed from the data reported by the authors using Henry’s law [1] at 10 °C. (3) The O2 contents computed in the study by Hampson et al. [2] from the PO2 measured in tap water and five brands of O2-waters (e.g., 226 mL·L−1 for 1184 mmHg in the brand 5 studied at exercise) are all in error. The correct value of O2-content for a PO2 = 1184 mmHg and at 10 °C is 61 mL·L−1 corresponding to 88 mg·L−1. The O2 content in «well-stirred» tap water with a PO2 of 127 mmHg is 6.6 mL·L−1 at 10 °C and 4 mL·L−1 at 37 °C (i.e., well below the value reported of 25 mL L−1) which is in line with the textbook value of 3 mL L−1 dissolved in arterial blood at a PO2 of ~100 mmHg and 37 °C [14]. (4) Not reported by the authors but found at website (https://www.reachforlife.com.au/Equine/EQ-Product.php, consulted 22 November 2021).
Figure 1Pulmonary responses during exercise: (a) pulmonary ventilation (VE), (b) oxygen uptake (VO2), (c) ventilatory equivalent of oxygen and (d) plasma lactate concentration with the three waters (mean ± SD; SD not shown past min 10 because n < 5; no significant difference was observed between the three waters, p > 0.05).
Figure 2Circulatory responses during exercise: (a) heart rate, (b) stroke volume (SV), (c) cardiac output and (d) arterio-venous difference in O2 (DavO2) with the three waters (mean ± SD; SD not shown past min 10 because n < 5; no significant difference was observed between the three waters, p > 0.05).
Blood gases and pH.
| Water | Rest | Min 5 | End of Exercise | |
|---|---|---|---|---|
| PaO2 (mmHg) | Control | 91.1 ± 8.8 | 86.4 ± 6.4 a | 86.1 ± 7.4 a |
| Injection | 93.1 ± 9.1 | 84.4 ± 6.7 a | 84.6 ± 8.5 a | |
| Electrolysis | 94.9 ± 6.8 | 86.1 ± 4.7 a | 83.5 ± 5.0 a | |
| PaCO2 (mmHg) | Control | 37.5 ± 1.9 | 30.7 ± 3.3 a | 27.3 ± 4.3 a,b |
| Injection | 36.7 ± 2.2 | 31.0 ± 3.5 a | 27.6 ± 4.3 a,b | |
| Electrolysis | 37.3 ± 2.3 | 30.6 ± 3.1 a | 27.9 ± 4.0 a,b | |
| SaO2 (%) | Control | 95.7 ± 1.2 | 95.0 ± 1.4 | 94.3 ± 1.3 |
| Injection | 95.5 ± 1.0 | 94.6 ± 0.8 | 94.0 ± 1.5 | |
| Electrolysis | 96.1 ± 1.1 | 95.0 ± 0.8 | 93.9 ± 1.0 | |
| pH | Control | 7.40 ± 0.03 | 7.40 ± 0.03 a | 7.26 ± 0.05 a,b |
| Injection | 7.39 ± 0.04 | 7.30 ± 0.03 a | 7 26 ± 0.04 a,b | |
| Electrolysis | 7.40 ± 0.03 | 7.30 ± 0.03 a | 7.25 ± 0.04 a,b |
Partial pressure of O2 and CO2, hemoglobin saturation (SaO2) and pH in arterialized blood at rest before exercise, at min 5 during the exercise and at the end of exercise with the three waters (mean ± SD; a significantly different from rest; b significantly different from min 5, p < 0.05; comparisons with two-way ANOVA for repeated measurements).
Pulmonary VO2 kinetics responses.
| Control | Injection | Electrolysis |
| |
|---|---|---|---|---|
| td1 (s) | 4.0 ± 9.8 | 4.9 ± 9.4 | 5.1 ±13.1 | 0.886 |
| τ1 (s) | 46.0 ± 15.4 | 43.5 ± 16.1 | 38.8 ± 16.8 | 0.060 |
| A1 (mL O2·min−1) | 2.98 ± 0.44 | 2.95 ± 0.40 | 2.91 ± 0.362 | 0.581 |
| td2 (s) | 208.5 ± 85.0 | 209.1 ± 82.3 | 189.9 ± 88.2 | 0.643 |
| τ2 (s) | 285.3 ± 96.0 | 254.6 ± 79.8 | 281.5 ± 101.5 | 0.266 |
| A’2 (mL O2·min−1) | 0.46 ± 0.18 | 0.53 ± 0.24 | 0.51 ± 0.20 | 0.773 |
Mean ± SD and p-values for the comparisons with one-way ANOVA for repeated measurements; td1 and td2, and τ1 and τ2 are respectively the time constants and the time delays for the fast and slow components of VO2 kinetics; A1 is the asymptotic amplitude of the fast component of VO2 kinetics; and A’2 is the amplitude of the slow component of VO2 kinetics computed as suggested by Borrani et al. [32].
Indices of ROS and damages in venous blood samples taken at rest.
| Control | Injection | Electrolysis |
| |
|---|---|---|---|---|
| Blood MDA content (μmol·L−1) | 3.09 ± 0.37 | 3.11 ± 0.37 | 3.06 ± 0.43 | 0.682 |
| Preserved thiol (μmol·g protein−1) | 6.22 ± 0.34 | 6.24 ± 0.42 | 6.22 ± 0.46 | 0.895 |
| Oxidized gluthatione (μmol·L−1) | 10.1 ± 5.1 | 10.7 ± 8.1 | 11.1 ± 12.7 | 0.758 |
| Reduced gluthatione (μmol·L−1) | 933 ± 266 | 869 ± 137 | 937 ± 444 | 0.856 |
| DNA damage (% tail) with FPG | 4.69 ± 1.09 | 4.77 ± 1.14 | 4.71 ± 1.19 | 0.600 |
Mean ± SD and p-values for the comparisons with one-way ANOVA for repeated measurements). MDA, malondialdehyde; FPG, formamidopyrimidine DNA glycosylase (DNA repair enzyme).